Skip to main content
search
Conference

Dutch Medicines Days

Conference: Dutch Medicines Days

Date: October 8 - 9, 2025

Location: Corpus Congress Centre Leiden, Netherlands

Certara is pleased to participate in the FIGON Dutch Medicines Days (DMD) Conference, taking place October 8–9, 2025, at the CORPUS Congress Centre in Leiden, Netherlands.

This annual meeting brings together scientists, clinicians, and industry leaders to exchange the latest insights in pharmaceutical research and development—bridging academia, industry, and government to advance innovative medicines.

We’re proud to present our poster, “Model-Based Meta-Analysis for Drug Development (MBMA): Towards a Robust Prediction for Early Clinical Decision Making.”

Authored by Li Qin, Paul Matthias Diderichsen, and Matt Zierhut, the poster highlights how Model-Based Meta-Analysis (MBMA) integrates data across multiple clinical trials to quantify treatment efficacy, predict outcomes for new drug combinations, and inform go/no-go and portfolio-level decisions across the drug development lifecycle.

Meet us there

Li Qin, Director of Consulting at Certara, will be attending the conference and presenting the poster on behalf of the team on Wednesday and Thursday, October 8–9, from 12:45–2:00 PM.

Li looks forward to connecting with peers and sharing how #MBMA continues to shape model-informed decision making in pharmaceutical development.

Where to hear Certara insights and Expertise

Wednesday and Thursday, October 8–9, from 12:45–2:00 PM
Model-Based Meta-Analysis for Drug Development (MBMA): Towards a Robust Prediction for Early Clinical Decision Making

Authors: by Li Qin, Paul Matthias Diderichsen, Matt Zierhut,

The poster highlights how Model-Based Meta-Analysis (MBMA) integrates data across multiple clinical trials to quantify treatment efficacy, predict outcomes for new drug combinations, and inform go/no-go and portfolio-level decisions across the drug development lifecycle.

You May Also Like

Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials
Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and TrialsBlog

Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address
5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps AddressBlog

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara
From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and CertaraOn-Demand Webinar

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara